Publications by authors named "Gillian Payne"

Background: The practical application of 'virtual' (computed) fractional flow reserve (vFFR) based on invasive coronary angiogram (ICA) images is unknown. The objective of this cohort study was to investigate the potential of vFFR to guide the management of unselected patients undergoing ICA. The hypothesis was that it changes management in >10% of cases.

View Article and Find Full Text PDF

Ambulatory electrocardiogram (AECG) monitoring is a common cardiovascular investigation. Traditionally, this requires a face-to-face appointment. In order to reduce contact during the COVID-19 pandemic, we investigated whether drive-by collection and self-fitting of the device by the patient represents an acceptable alternative.

View Article and Find Full Text PDF

Glycosylation is a complex multienzyme-related process that is frequently deregulated in cancer. Aberrant glycosylation can lead to the generation of novel tumor surface-specific glycotopes that can be targeted by antibodies. Murine DS6 mAb (muDS6) was generated from serous ovary adenocarcinoma immunization.

View Article and Find Full Text PDF

Host cell proteins (HCPs) are process-related impurities derived from the host organism such as Chinese hamster ovary (CHO) cells used for the production of therapeutic mAbs in biopharmaceuticals and potentially pose a risk to patient safety and product efficacy. A number of HCPs have been reported as exceptionally difficult to remove and persist across downstream purification operations into final drug product because they exhibit association with mAbs. Therefore, understanding of HCP impurities and the mAb itself will provide insights into the rational design of efficient downstream process.

View Article and Find Full Text PDF
Article Synopsis
  • * The immune response to these biological drugs is crucial since it can impact their effectiveness and safety, leading to the need for thorough monitoring of patient responses.
  • * Researchers created a highly specific anti-idiotype antibody that targets the M9346A component of mirvetuximab soravtansine, which can be used for sensitive assays to track anti-drug antibodies in patients.
View Article and Find Full Text PDF
Article Synopsis
  • A majority of ovarian and non-small cell lung adenocarcinoma cancers produce high levels of folate receptor α (FRα), which is targeted by a new anti-FRα antibody-drug conjugate (ADC) called IMGN853.
  • IMGN853 combines a specific antibody (M9346A) with a potent drug that disrupts cell microtubules, leading to cell-cycle arrest and death in FRα-positive cancer cells.
  • The ADC demonstrated strong effectiveness in preclinical models and has potential for treating tumors that express FRα, along with the ability to target nearby FRα-negative cells, making it a promising option for patients with these types of cancers.
View Article and Find Full Text PDF

Incidental left bundle-branch block occurs in up to 1.5% of healthy adults without symptoms or signs of cardiovascular disease. It may be found during investigation for non-cardiac disease, during preoperative assessment, private health screening or inpatient monitoring.

View Article and Find Full Text PDF

In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels of steric hindrance around the disulfide bond, in order to investigate the relationship between stability to reduction of the disulfide linker and antitumor activity of the conjugate in vivo. The conjugates were first tested for stability to reduction by dithiothreitol in vitro and for plasma stability in CD1 mice. It was found that the conjugates having the more sterically hindered disulfide linkages were more stable to reductive cleavage of the maytansinoid in both settings.

View Article and Find Full Text PDF

Advances in immunoconjugate technology have revitalized the "magic bullet" concept of immunotherapeutics for the treatment of cancer. The growing availability of "human" antibodies, the increased epitope repertoire due to genomics and proteomics efforts, and advances in the means of identification and production of tumor-specific antibodies have greatly increased the potential for cancer therapeutic opportunities. Furthermore, the realization that effector molecule potency must be sufficiently high to be effective at concentrations that might realistically be delivered to the tumor site on an antibody carrier has greatly spurred the fields of medicinal chemistry and radionuclide chelate chemistry to produce such molecules.

View Article and Find Full Text PDF